







Hosted by Paul Webber paul@webbertraining.com www.webbertraining.com











| | | Ke | y Consid | eration | S | |
|---------|--|---------------|--|--|---|--|
| | | Goal | Key question | Key considerations and pot | tential | |
| DS | Rig | Right test | Is the test appropriate for the clinical setting? | Sensitivity and specificity Predictive values Testing volumes Diagnostic yield Laboratory feasibility Cost | | |
| | | Right patient | Will the clinical care of the patient be affected by the test result? | Canical impact Laboratory test utilization co Automatic laboratory reflex CPOE decision support Appropriate use criteria Indication selection Prior authorization Benchmarking Canadron mutadion | ommittee | |
| | | Right time | Will the result be available in time to optimally affect care? | Specifien rejection Time to specimen receipt Centralized vs point-of-care On-demand vs batched test Specimen preparation time Run time Result reporting time | testing ing | |
| | Carl | 2 | | ······ | Key considerations and extential starts along | |
| AS- | Right interp | retation | Will the clinician understand the test result? | | Result report language Selective reporting of relevant results AS prospective audit and feedback AS real time decision cumport | |
| | Right antimicrobial Right time "AS, antimicrobial stewardship. | | Will the clinician appropriately modify antimicrobials based on the test result? Will the clinician act upon the test result promptly? | | As real-unite decision support Clinical practice guidelines EMR-based decision support with result reporting AS prospective audit and feedback AS real-time decision support EMR reporting Results called with readback reporting AS prospective audit and feedback AS real-time decision support | |
| | | | | | | |





| | | | | u DS Strat | egles |
|------------------|--|--|---|---|---|
| TABLE I. | Examples of The | reated braghosde ore nardsnip brateg | au 3 | Diagnostic Stewardship Strategies | |
| HAI | Guidelines | Guidance to Support Stewardship Approach | Preanalytic | Analytic | Postanalytic |
| CAUTI | ACCCM/ IDSA guidelines for evaluation of new fever in critically ill patients ¹⁹ | Urine culture should only be obtained in febrile catheterized patients when urinary tract is suspected as a source or if urinary obstruction, neutropenia, or recent surgery is present. Urine dipstick is not recommended for catheterized vatients. | Multifaceted approach in an ICU setting including 'stewardship of culturing, 'reduced CAUTI rates by a third. ¹⁸ BPA discouraging dipsticks for catheterized patients. | Reflex urine culture protocol instituted for immunocompetent ICU patients associated with lower CAUTI rates. The lab performed urine culture only if pyuria was present on urinalysis. ²⁰ | Clear interpretative language (eg. "likely contaminant") attached to result. |
| HABSI/ CLABSI | IDSA clinical practice guidelines for intravascular catheter- related infection ⁶ | Blood cultures should be obtained by a specialized phlebotomist. Catheter- drawn cultures to be done only when catheter-related BSI is suspected, along with a peripheral sample. Meta-analysis shows catheter-obtained specimens more likely to be contaminated versus | Policy discouraging routine blood culture samples drawn from central lines plus reducation of phlebotomist reduced blood culture contamination and CLABSIs related to contamination. ⁹ | Use of molecular microarray for gram-positive blood cultures shortens time to pathogen identification and appropriate antimicrobial therapy for patients with VRE bacteremia. ²⁷ | Rapid microarray results coupled with mandatory infectious diseases consultation for positive gram-positive cultures reduced mortality due to <i>S. aureus</i> bacteremia. ²⁸ |
| Ma | adden GR, et a duce test use. | al. Diagnostic Stewardship for ICHE 2018;39:214-18. | healthcare-associated infe | ctions opportunities and chal | lenges to safely |

| Camp Table. Steps at Wh | DIES OF H | IAI-Rela | ted D | S Strategi |
|---|--|--|---|--|
| | Ordering (Preanalytic) | Collection (Preanalytic) | Processing (Analytic) | Reporting (Postanalytic) |
| General principles | Test only if clinical presentation is consistent with the infectious etiology (high pretest probability) | Pay attention to sample collection and transport, to optimize yield and reduce contamination | Use adjunctive laboratory tests to distinguish colonization from infection | Report results in a format that guides appropriate practice |
| Urine cultures | Test only when symptoms suggest urinary tract infection or, if asymptomatic, concordant with guidelines (eg, urologic surgery, pregnancy) | Use aseptic technique- midstream clean catch after periurethral cleansing Obtain catheter sample from collection port (not bag), prefer newly inserted catheter | Only perform urine culture if pyuria present | Text interpreting result, eg, "multiple organisms indicating likely contamination" "no pyuria, culture not performed" Selective reporting of antibiotic susceptibilities—display preferred antibiotics only |
| Blood cultures | Test only when symptoms of infection present (fever) Avoid repeat cultures unless concern for persistent or endovascular infection | Use aseptic technique—prefer peripheral samples obtained by trained phlebotomists Avoid catheter draws | Consider rapid testing on initial positive results, eg, polymerase chain reaction, PNA-FISH, MALDI-TOF | Text interpreting result, eg, "likely skin contaminant", "Staphylococcus aureus, likely pathogen consider infectious diseases consult" Selective reporting of antibiotic susceptibilities |
| Clostridium difficile testing | Test only when disease likely (eg, recent antibiotic exposure, >3 loose stools/d, duration >24 h, and no recent laxative use) Avoid tests of cure | Only collect and send loose stool (ie, that conforms to the container) | Consider use of a testing algorithm that includes toxin immunoassay | Text interpreting result, eg, "toxin-/PCR+ indicating possible colonization rather than disease" |
| Molecular detection panels (ie, "syndromic testing") | Test only when pretest probability moderate to high for ≥2 targets on the panel, and when results will influence management | Use recommended collection and transport conditions to reduce contamination and optimize yield | Follow stringent contamination prevention guidance in the laboratory to avoid false-positive results | Selective suppression of results for tests on panel if other testing approach used in the laboratory (eg. <i>C difficile</i> testing on stool pathogen panel) Text interpreting results discussing colonization |
| Forms of automation | Clinical decision support requiring documentation of symptoms Hard stops for contraindications— eg, laxative use within 48 h of <i>C</i> difficile test) | Recording site and method of collection Orders requiring supplementary tests-eg, urinalysis before urine culture | Laboratory support systems performing cascades of tests | Prepopulated reports that can be reviewed and modified by laboratory personnel |
| Clinician education | Yes | No | No | Yes |
| Abbreviations: PNA- | FISH, peptide nucleic acid-fluoresce | nce in situ hybridization; MALDI-TC | F, matrix-assisted laser des | timicrobial use IAMA |

















































| The I | Role of N Nurses "Unree | JURS | ing in AS Prog | rams |
|-------|---|--|---|------|
| | ASP Tasks on Admission | Core Element | "Unrecognized" Nursing Role | |
| | Triage & isolation | A, DE, E | Identifies need isolation | |
| | Allergy History | A, DE, E | Takes allergy history Medication reconciliation | |
| | Cultures | A, DE, E | Collects before antibiotics Monitors results | |
| | Timely antibiotics | DE, A, T | Receives orders & reviews details, Checks allergies, administers | |
| | White Paper- Redefining the AS Team: Recommendations from the ANS https://www.cdc.goulantherics.usubhashbcaor/phi/ANA/CPC-ashtpape Ofaro et. Al. (Do. 2016; 52:11): 34-89. Okans et al. AlN. 2017; 117: 311: 5 A = Action DE= Drug avanation. E= Education | VCDC Workgroup on the Role of RNs er off 8-63. | in Mospital AS Practices | |
| | re recon, on long expense, L- caucator | | | |
| | | | | |
| | | | | 39 |































| wv | ww.webbertraining.com/schedulep1.php |
|--------------------|--|
| August 15, 2019 | (FREE Teleclass) BED BUG PREVENTION IN THE HEALTHCARE SETTING Speaker: Dr. Marcia Anderson, Environmental Protection Agency, United States |
| August 22, 2019 | HOW TO ENGAGE AND EDUCATE NURSES IN EVIDENCE-BASED PRACTICE Speaker: Eileen J. Carter, Columbia University School of Nursing |
| September 5, 2019 | MEASURES TO PREVENT AND CONTROL VRE: DO THEY REALLY MATTER? Speaker: Dr. Hilary Humphreys, The Royal College of Surgeons in Ireland |
| September 12, 2019 | (FREE Teleclass) MEAT, MONKEYS, AND MOSQUITOES: A ONE HEALTH PERSPECTIVE ON EMERGING DISEASES Speaker: Prof. Laura Kahn, Woodrow Wilson School of Public and International Affairs, Princeton University |
| September 22, 2019 | (FREE European Teleclass – Broadcast live from the Infection Prevention Society conference) Cottrell Lecture CHALLENGES AND OPPORTUNITIES IN INFECTION PREVENTION AND CONTROL Speaker: Prof. Brett Mitchell, Avondale College of Higher Education, Australia |
| September 24, 2019 | (FREE European Teleclass – Broadcast live from the Infection Prevention Society <u>conference</u>) Avliffe Lecture PNEUMOCYSTIS - AN IMPORTANT HEALTHCARE- |

